New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 4, 2014
07:19 EDTTNXP, APGI, XXII, NEO, CLIR, LOCM, HIPP, FNJNLD Micro to hold a conference
LD Micro 4th Invitational Conference to be held in Los Angeles on June 4.
Check below for free stories on TNXP;APGI;XXII;NEO;CLIR;LOCM;HIPP;FNJN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
08:33 EDTFNJNFinjan Holdings announces Markman Hearing set for August 22
Finjan Holdings announced an update on its lawsuit against Blue Coat Systems. Finjan Holdings' subsidiary Finjan, filed a patent infringement lawsuit against Blue Coat on August 28, 2013. In accordance with the local patent rules of the U.S. District Court for the Northern District of California, a Claim Construction or "Markman" Hearing is set for August 22. The Markman hearing is an important pre-trial event in a patent lawsuit, wherein the Court will construe the asserted patent claims after consideration of the parties' evidence.
July 17, 2014
13:54 EDTNEONeoGenomics up 21% after reporting Q2 earnings, raising FY14 guidance
Shares of NeoGenomics are trading up 21% in afternoon trading after the company reported Q2 earnings this morning. The company reported in-line earnings, better-than-expected revenue, and raised its FY14 revenue guidance.
07:07 EDTNEONeoGenomics sees 2014 EPS 0c-3c, consensus 3c
Raises 2014 revenue view to $83.0M-$86.0M from $73M-$77M, consensus $78.56M.
07:05 EDTNEONeoGenomics sees Q3 EPS (1c)-1c, consensus 1c
Sees Q3 revenue $22.0M-$22.5M, consensus $20.02M.
07:03 EDTNEONeoGenomics reports Q2 EPS 1c, consensus 1c
Reports Q2 revenue $20.7M, consensus $19.84M.
July 11, 2014
17:05 EDTFNJNFinjan Holdings files $100M mixed securities shelf
Subscribe for More Information
16:22 EDTFNJNFinjan Holdings appoints Phillip Hartstein as CEO
Subscribe for More Information
08:36 EDTTNXPTonix Pharmaceuticals raises $7.8M in a registered direct offering
Tonix announced it has agreed to sell 657,000 shares of common stock in a registered direct offering at a price of $11.90 per share for aggregate gross proceeds of approximately $7.8M. Tonix expects to use the net proceeds of the offering to support the continued development of TNX-102 SL for the treatment of fibromyalgia, to initiate clinical trials of TNX-102 SL for the treatment of post-traumatic stress disorder, to initiate clinical trials of TNX-201 for episodic tension-type headache, and further develop our other pipeline programs, and for working capital and other general corporate purposes, and possibly acquisitions of other companies, products or technologies, though no such acquisitions are currently contemplated. Roth Capital Partners acted as the exclusive placement agent for the offering.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use